Table 5.
Best response and progression free survival
| MTDa (n=44) n (%) | NSCLC (n=22) n (%) | |
|---|---|---|
| Evaluablec | 39 (89) | 19 (86) |
| Stable disease | 28 (64) | 16 (73) |
| Confirmedb | 15 (34) | 8 (36) |
| Unconfirmedc | 13 (30) | 8 (36) |
| Progressive disease | 10 (23) | 4(18) |
| Unable to determine | 6(14) | 2 (9) |
| Median PFS, months | 3.7 | 4.4 |
MTD maximum tolerated dose; PFS progression-free survival
a
Includes all patients from Phase 1 to 2a at the MTD dose
b
Confirmed are patients with ≥1 repeat scan every 8 weeks with continued stable disease
c
Unconfirmed are patients without repeat scan at 8 weeks demonstrat-ing stable disease